Dr. Ayan R. Patel, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 890
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Boston University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
MA license 81167
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Beth Israel Deaconess Medical Center Boston, MA
- Boston Medical Center Boston, MA
- Southcoast Hospitals Group Fall River, MA
- Tufts Medical Center Boston, MA
- Melrosewakefield Healthcare Melrose, MA
Medical groups
- Cardiovascular Center at Tufts Medical Center Inc (97 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 890
- Services billed
- 1,407
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 473 | 451 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 456 | 375 |
| Ultrasound of heart, follow-up | 104 | 89 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 91 | 88 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 68 | 23 |
| Established patient office or other outpatient visit, 40-54 minutes | 65 | 48 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 55 | 54 |
| Established patient office or other outpatient visit, 30-39 minutes | 51 | 39 |
| Ultrasound of heart with probe in esophagus, with report | 39 | 39 |
| Ultrasound of heart blood flow, valves and chambers | 30 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Vyndamax (tafamidis) | 347 |
| Metoprolol Succinate Other prescribers in Boston, MA | 52 |
| Jardiance (empagliflozin) Other prescribers in Boston, MA | 52 |
| Lisinopril Other prescribers in Boston, MA | 45 |
| Repatha Sureclick (evolocumab) Other prescribers in Boston, MA | 40 |
| Furosemide Other prescribers in Boston, MA | 38 |
| Atorvastatin Calcium Other prescribers in Boston, MA | 37 |
| Ezetimibe Other prescribers in Boston, MA | 23 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Boston, MA | 22 |
| Praluent Pen (alirocumab) Other prescribers in Boston, MA | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 15 payments worth $8,887 in total to this clinician.
| Pfizer Inc. | $5,790 |
|---|---|
| Bridgebio Pharma, Inc. | $2,763 |
| Genzyme Corporation | $333 |
| Consulting Fee | $8,398 |
|---|---|
| Food and Beverage | $441 |
| Compensation for services other than consulting (speaking, faculty) | $47.30 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Nov 12, 2025 | Consulting Fee VYNDAQEL · CARDIOVASCULAR | $4,400 |
| Bridgebio Pharma, Inc. Jun 16, 2025 | Consulting Fee Attruby · Cardiomyopathy | $2,565 |
| Pfizer Inc. Nov 12, 2025 | Consulting Fee VYNDAQEL · CARDIOVASCULAR | $1,100 |
| Genzyme Corporation Feb 12, 2025 | Consulting Fee | $167 |
| Genzyme Corporation Dec 15, 2025 | Consulting Fee | $83.33 |
| Genzyme Corporation Dec 15, 2025 | Consulting Fee | $83.33 |
| Pfizer Inc. Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAQEL · CARDIOVASCULAR | $47.30 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $9,515 in research payments for these studies, mostly to the institutions running them.
- A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.